QNRX QUOIN PHARMACEUTICALS LTD US FDA Inspections 8-K Filing 2025 - Pre-Market Approval On May 20, 2025, Quoin Pharmaceuticals Ltd. announced that it has received Orphan Drug Designation in Europe for its lead product QRX003, aimed at treating Netherton Syndrome.Get access to all SEC 8-K filings of the QUOIN PHARMACEUTICALS LTD